A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma - Report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group

dc.creatorSantini, G
dc.creatorDe Souza, C
dc.creatorAversa, S
dc.creatorPatti, C
dc.creatorTedeschi, L
dc.creatorCandela, M
dc.creatorOlivieri, A
dc.creatorChisesi, T
dc.creatorRubagotti, A
dc.creatorCenturioni, R
dc.creatorNardi, V
dc.creatorCongiu, M
dc.creatorGennaro, M
dc.creatorTruini, M
dc.date2004
dc.dateMAY
dc.date2014-11-16T23:06:36Z
dc.date2015-11-26T17:37:41Z
dc.date2014-11-16T23:06:36Z
dc.date2015-11-26T17:37:41Z
dc.date.accessioned2018-03-29T00:19:20Z
dc.date.available2018-03-29T00:19:20Z
dc.identifierBrazilian Journal Of Medical And Biological Research. Assoc Bras Divulg Cientifica, v. 37, n. 5, n. 719, n. 728, 2004.
dc.identifier0100-879X
dc.identifierWOS:000221369800014
dc.identifier10.1590/S0100-879X2004000500014
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/53917
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/53917
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/53917
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1286019
dc.descriptionThe objective of this multicenter prospective study was to determine the clinical efficacy and toxicity of a polychemotherapeutic third generation regimen, VACOP-B, with or without radiotherapy as frontline therapy in aggressive localized non-Hodgkin's lymphoma. Ninety-three adult patients (47 males and 46 females, median age 45 years) with aggressive localized non-Hodgkin's lymphoma, 43 in stage I and 50 in stage II (non-bulky), were included in the study. Stage I patients received VACOP-B for 6 weeks plus involved field radiotherapy and stage II patients received 12 weeks VACOP-B plus involved field radiotherapy on residual masses. Eighty-six (92.5%) achieved complete remission and 4 (4.3%) partial remission. Three patients (3.2%) were primarily resistant. Ten-year probability of survival, progression-free survival and disease-free survival were 87.3, 79.9 and 83.9%, respectively. Eighty-four patients are surviving at a median observation time of 57 months (range: 6-126). Statistical analysis showed no difference between stages I and II in terms of response, ten-year probability of survival, progression-free survival or disease-free survival. Side effects and toxicity were negligible and were similar in the two patient groups. The results of this prospective study suggest that 6 weeks of VACOP-B treatment plus radiotherapy may be the therapy of choice in stage I aggressive non-Hodgkin's lymphoma. Twelve weeks of VACOP-B treatment with or without radiotherapy was shown to be effective and feasible for stage II. These observations need to be confirmed by a phase III study comparing first and third generation protocols in stage I-II aggressive non-Hodgkin's lymphoma.
dc.description37
dc.description5
dc.description719
dc.description728
dc.languageen
dc.publisherAssoc Bras Divulg Cientifica
dc.publisherSao Paulo
dc.publisherBrasil
dc.relationBrazilian Journal Of Medical And Biological Research
dc.relationBrazilian J. Med. Biol. Res.
dc.rightsaberto
dc.sourceWeb of Science
dc.subjectlocalized aggressive non-Hodgkin's lymphoma
dc.subjectVACOP-B
dc.subjectradiotherapy
dc.subjecttoxicity
dc.subjectProspective Randomized-trial
dc.subjectLarge-cell Lymphoma
dc.subjectMacop-b
dc.subjectStage Intermediate
dc.subjectBrief Chemotherapy
dc.subjectRadiation-therapy
dc.subjectResponse Criteria
dc.subjectElderly-patients
dc.subjectBone-marrow
dc.subjectGrade
dc.titleA third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma - Report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución